ArticlePrecision radiation oncology2026
Engineering dosimetric excellence in total body irradiation: Tomotherapy-driven protocols for precision and reproducibility.
Article in Precision radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Problem: The clinical feasibility, dosimetric reproducibility, and in vivo accuracy of a tomotherapy-based total-body irradiation (TBI) protocol in a large cohort of patients undergoing hematopoietic stem cell transplantation (HSCT) is evaluated. Methods: Patients (128 patients with hematological malignancies undergoing TBI with helical tomotherapy) were simulated in dual orientations (head-first and feet-first supine) to accommodate extended anatomical lengths. Plans were generated as separate upper and lower components with structured gradient overlap zones and then composited for delivery. Quality assurance included an ArcCHECK 3D diode array for patient-specific gamma analysis (3%/3 mm criteria), point-dose verification, and in vivo dosimetry. The gamma pass rates, regional dose deviations, and Pearson correlation coefficients were analyzed. Statistical evaluation was performed using the Shapiro-Wilk test, Levene's test, and ANOVA. Results: All treatment plans met the institutional constraints for planning target volume (PTV) coverage and organs at risk sparing. The mean D95% of the PTV consistently exceeded 95% of the prescribed dose, ensuring robust target coverage. This reflects excellent conformity with the planned dose distribution. Region-wise gamma pass rates exceeded 97% in all areas except junctions, where rates were slightly lower owing to dose gradients. The point-dose agreement showed tight clustering within the ±3% range, with the pelvis exhibiting the most significant positive shift. The in vivo optically stimulated luminescence dosimeter dose remained within the clinically acceptable range of 0.8-1.2 Gy. A strong interregional correlation ( Conclusion: Tomotherapy-based TBI demonstrated high dosimetric precision, reproducibility, and workflow efficiency. This protocol offers a clinically reliable approach for modern TBI delivery in transplant conditioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.